US Stock Insider Trading | Nurix Therapeutics Disclosed One Insider Transaction on March 2

K-LinePoet · 2026-03-12T22:21:33+00:00

Nurix Therapeutics (NRIX) disclosed on March 2, 2026 that executive Ring Christine sold 8,148 shares of stock at a transaction price of $15.44 per share, for a total amount of approximately $125,800. In recent insider trading, the executive also sold 14,300 shares on February 9, showing active trading. Nurix is a clinical-stage biopharmaceutical company focused on targeted protein degradation, collaborating with multiple pharmaceutical companies to develop drugs for treating cancer and inflammatory diseases.

K-LinePoet

2026-03-12 22:21:33

Abstract generation in progress

On March 2, 2026, Nurix Therapeutics (NRIX) disclosed an insider trading activity. Executive Ring Christine sold 8,148 shares on that date.

[Recent Insider Trading]

Disclosure Date	Position	Name	Trading Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 2, 2026	Executive	Ring Christine	March 2, 2026	Sell	8,148	15.44	$125,800
February 9, 2026	Executive	Ring Christine	February 9, 2026	Sell	14,300	16.66	$237,600
February 3, 2026	Executive	Hansen Gwenn	February 3, 2026	Buy	31,300	0.84	$2,630
January 30, 2026	Executive	Hansen Gwenn	January 30, 2026	Sell	98	17.37	$1,702.43
January 30, 2026	Executive	van Houte Hans	January 30, 2026	Sell	73	17.37	$1,268.13
January 30, 2026	Executive	van Houte Hans	January 30, 2026	Sell	3,588	16.58	$59,500
January 30, 2026	Executive	Ring Christine	January 30, 2026	Sell	88	17.37	$1,528.71
January 30, 2026	Executive	Ring Christine	January 30, 2026	Sell	4,333	16.58	$71,900
January 30, 2026	Executive	Hansen Gwenn	January 30, 2026	Sell	4,797	16.58	$79,500
January 20, 2026	Executive	Ring Christine	January 20, 2026	Buy	3,760	1.86	$6,993.60

[Company Profile]

Nurix Therapeutics, Inc. was incorporated on August 27, 2009, in Delaware, with headquarters in Brisbane, California. It is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases. Supported by an AI-integrated discovery engine and deep expertise in E3 ligase biology, the company advances a differentiated approach to translating protein degradation science into clinical therapies. Nurix’s wholly owned pipeline includes drug candidates targeting Bruton’s tyrosine kinase (BTK) and Casitas B-lineage lymphoma proto-oncogene B (CBL-B), along with additional degraders and degrader antibody-drug conjugates in preclinical development. Nurix collaborates with global pharmaceutical partners including Gilead Sciences, Sanofi, and Pfizer, conducting discovery programs for multiple candidates under co-development and co-commercialization arrangements.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.